YB1 rt PA
Alternative Names: Modified version YB1 for thrombolysis; YB1 RT PA - HKND YB1 PHARMACEUTUCAL; YB1-rt-PALatest Information Update: 11 Jul 2022
At a glance
- Originator University of Hong Kong
- Developer HKND YB1 PHARMACEUTUCAL
- Class Bacteria; Plasminogen activator enzymes; Thrombolytics
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Thrombosis
Most Recent Events
- 11 Jul 2022 Preclinical trials in Thrombosis in China (Parenteral) before July 2022 (HKND YB1 PHARMACEUTUCAL website, July 2022)
- 01 Jan 2021 HKND YB1 PHARMACEUTICAL establishes a strategic partnership with HKU of the University of Hong Kong and obtains the exclusive license and commercial exploitation right of all YB1 patents (HKND YB1 PHARMACEUTICAL website, July 2022)
- 01 Jan 2013 University of Hong Kong has patents protection for YB1 related invention in the US, the European Union and China (HKND YB1 PHARMACEUTICAL website, July 2022)